President Trump is initiating a new investigation into drug prices, aiming to compel foreign nations to pay the same as Americans for their...

Wall Street analysts on average expect Pfizer to earn $3.07 per share, according to IBES data from Refinitiv.

According to sources, both deals were at an advanced stage, and Fosun had formally proposed terms for acquiring a stake in the companies, o...

The discussions covered issues relating to the fiscal deficit and general government debt and the constraints in drawing up a path for cons...

Gawande was chosen Wednesday to run a startup company that aims to improve medical care and lower health costs for the more than 1 million ...

Israeli will replace Abhijit Mukherjee, who retires following his 15-year stint at the company. Mukherjee's tenure as COO was marked with u...

As part of its medium term strategy, the company is also looking at increasing presence in complex generics, Glenmark said in a presentatio...

Regulatory and clinical development expertise and the might to take products through the commercialization stages offer a natural edge to b...

US Congressional hearings on few firms that had astronomically hiked drug prices have scared CEOs who are not considering any amount of pri...

South Indian Bank and Banco Products (India) will announce their financial results for the quarter ended December 31, 2016 on Wednesday.

Analysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...

The company, which competes with Indian IT firms like Tata Consultancy Services and Infosys, said it expects this year to be a "little toug...

Firm's net income rose to $423.4 million, or 69 cents per share, in the fourth quarter from $362.9 million, or 59 cents per share, a year e...

Cognizant Technology Solutions sprang a surprise and predicted an indifferent first quarter citing lower spending from key customers.

“The IHH Healthcare Berhad Group has purchased around 74 per cent stake for Rs 2,150 crore, which includes Rs 350-crore debt.”

Cognizant turned in a solid quarterly performance that came in ahead of expectations and marginally raised its annual guidance to 19.3%.

The deal may not include Aman's New Delhi property, and, if concluded, will help India’s largest real estate company cut its Rs 14,000 cror...